clinicaltrialsarena

MSD’s Phase IIb study of tulisokibart achieves primary endpoint

In the study, 72% of patients in the high-dose arm and 64% in the medium-dose arm achieved HiSCR50. Credit: 89stocker / Shutterstock.com. Merck & Co (MSD) has reported that the Phase IIb MK-7240-012 ...
clinicaltrialsarena

EASD 2026: Oral semaglutide drives weight loss after switch from injectable GLP-1s

Oral semaglutide maintains weight-loss progress after injectable GLP-1 therapy, strengthening its case as an oral alternative.
clinicaltrialsarena

Invivyd’s Covid-directed mAb hits Phase III safety goals

Invivyd’s Covid-targeting mAb was proven more safe and tolerable than Pfizer and BioNTech’s Comirnaty as per the trial’s endpoints. Credit: Corona Borealis Studio / Shutterstock.com. Invivyd’s ...
clinicaltrialsarena

VectorY broadens global PIONEER-ALS clinical trial cohort

ALS is a fatal neurodegenerative condition with no cure and limited treatment options for symptom management. Credit: Andrzej Rostek/Shutterstock.com. VectorY Therapeutics has expanded the study size ...
clinicaltrialsarena

Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial

Vasomune Therapeutics will focus on data quality, review, cleaning, site closeout, and database lock preparations. Credit: PanuShot / Shutterstock.com. Vasomune Therapeutics has completed enrolment in ...
clinicaltrialsarena

IMS26: Key readouts rock the multiple myeloma field amid shifting landscape

The Clinical Trials Arena editorial team brings you the highlights from the IMS 2026 Congress in Glasgow, Scotland. Credit: David A Litman / Shutterstock.com. In recent years, the multiple myeloma ...
clinicaltrialsarena

Akeso begins Phase III study of cadonilimab for gastric cancer

The bispecific antibody is intended for treating advanced gastric cancer. Credit: SewCreamStudio/Shutterstock.com. Akeso has commenced a global Phase III clinical ...
clinicaltrialsarena

European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance

In an open letter to European governments, the chairs of AstraZeneca, Boehringer Ingelheim, Chiesi, Ipsen, GSK, Novo Nordisk, Novartis, Roche and Sanofi expressed concern. Credit: Vladimir ...
clinicaltrialsarena

Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen

FUS-ALS is a rare, rapidly progressing ALS form, with no currently approved therapies directly addressing its genetic cause. Credit: Faizal Ramli / Shutterstock.com. Otsuka Pharmaceutical Development ...
clinicaltrialsarena

AstraZeneca’s cancer pipeline posts two wins and a loss

AstraZeneca has shared late-stage readouts for three of its oncology portfolio medicines: Enhertu, Tagrisso and Etcamah. Credit: Mats Wiklund / Shutterstock.com. It has been a mixed few days for ...
clinicaltrialsarena

Biohaven’s epilepsy drug hit with FDA clinical hold

Opakalim is currently in development for the treatment of focal onset seizures. Credit: Berit Kessler / Shutterstock.com. The US Food and Drug Administration (FDA) has placed a partial clinical hold ...